The estimated Net Worth of Reinhard Kandera is at least $1.58 Million dollars as of 21 August 2023. Mr. Kandera owns over 7,000 units of Hookipa Pharma Inc stock worth over $227,526 and over the last 6 years he sold HOOK stock worth over $0. In addition, he makes $1,348,480 as Chief Financial Officer and Director at Hookipa Pharma Inc.
Reinhard has made over 3 trades of the Hookipa Pharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of HOOK stock worth $5,110 on 21 August 2023.
The largest trade he's ever made was buying 12,000 units of Hookipa Pharma Inc stock on 30 June 2023 worth over $10,560. On average, Reinhard trades about 2,250 units every 4 days since 2019. As of 21 August 2023 he still owns at least 43,092 units of Hookipa Pharma Inc stock.
You can see the complete history of Mr. Kandera stock trades at the bottom of the page.
Dr. Reinhard Kandera serves as Chief Financial Officer, Director of the Company. Mr. Kandera served as the Chief Financial Officer and Member of the Management Board of Valneva SE, or Valneva, from May 2013 to April 2017. Prior to Valneva, he served as Chief Financial Officer of Intercell AG, or Intercell, from March 2009 to May 2013 and as Member of Intercell's Management Board from November 2009 to May 2013, which merged with Vivalis SA to become Valneva in May 2013. Mr. Kandera received doctorate degrees in Business Administration and in Law from the Vienna University. Our Board of Directors believes that Mr. Kandera's experience gained from serving as our Chief Financial Officer, combined with his previous qualifications and the skills and experience he has developed during his extensive career in the life sciences industry, qualify him to serve as a member of our Board of Directors.
As the Chief Financial Officer and Director of Hookipa Pharma Inc, the total compensation of Reinhard Kandera at Hookipa Pharma Inc is $1,348,480. There are 1 executives at Hookipa Pharma Inc getting paid more, with Joern Aldag having the highest compensation of $6,367,980.
Reinhard Kandera is 51, he's been the Chief Financial Officer and Director of Hookipa Pharma Inc since 2017. There are 11 older and 5 younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
Reinhard's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro..., and Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: